Reference tissue methods to estimate neuroreceptor binding are not applicable to [
Introduction
An F-18-labeled muscarinic-2 (M2) subtype-selective agonist, 3-(3-(3- [18 F ]flouropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6 tetrahydro-1-methylpyridine ([ 18 F]FP-TZTP), has been successfully used for positron emission tomography (PET) imaging of central M2 cholinergic receptors in human (Cohen et al, 2003) . In these [
18 F]FP-TZTP PET studies, the gray matter distribution volume of [ 18 F]FP-TZTP (a measure of M2 receptor binding) was greater in aged healthy subjects with an apolipoprotein E-e4 (APOEe4) allele(s) that confers an increased susceptibility to Alzheimer's disease than those without an APOEe4 allele (Cohen et al, 2003) . The greater M2 binding found in these studies is consistent with decreased synaptic concentrations of acetylcholine in aged subjects with an APOE-e4 allele and, therefore, the findings support the hypothesis of the involvement of the cholinergic system in Alzheimer's disease and age-related cognitive changes.
Kinetic modeling studies of [ 18 F]FP-TZTP PET data have shown that [ 18 F]FP-TZTP time-activity data can be described by the one-tissue (1T) compartment model with two kinetic rate constants, K 1 (mL/min per cm 3 , the rate constant for transfer from plasma to the tissue) and k 2 (min À1 , the tissue clearance rate constant) (Carson et al, 1998 (Carson et al, , 1999 . Because of the widespread distribution of M2 receptors throughout the brain, there is no suitable receptor-free reference region for [ 18 F]FP-TZTP. Therefore, noninvasive reference tissue methods (Ichise et al, 1996 (Ichise et al, , 2003 Logan et al, 1996 Logan et al, , 2001 Lammertsma and Hume, 1996) that allow estimation of binding potential (BP ND ; Mintun et al, 1984) without arterial data are not applicable to [ 18 F]FP-TZTP data, although the 1T model is applicable for all regions. Instead, the total distribution volume (V T (mL/cm 3 )) of [ 18 F]FP-TZTP has been used as an M2 receptor parameter for the comparison of subjects belonging to different groups or under different experimental conditions (Carson et al, 1998; Cohen et al, 2003) . Estimation of V T unlike that of BP ND , however, requires the acquisition of invasive arterial blood samples and technically demanding corrections for radiolabeled metabolites, which are used as an estimate of the arterial input function.
To avoid the invasive arterial sampling, one approach may be the use of standardized input curves (Takikawa et al, 1993; Onishi et al, 1996) . However, standard input curves need to be established a priori and, furthermore, intersubject differences in metabolite-corrected arterial plasma data must be small. Otherwise, compartment model fitting of individual PET data with a standard input curve may not be accurate. Another noninvasive approach to estimate the input function involves mathematical extraction of vascular time-activity data from dynamic PET data, which then can be used as the input function in certain situations (Feng et al, 1997; Liptrot et al, 2004) . However, the latter approach would not be applicable to neuroreceptor tracers such as [ 18 F]FP-TZTP, where the input function requires corrections for radiolabeled metabolites.
Alternatively in this study, we evaluated a new method to estimate, without the use of arterial input functions or a receptor-free reference region, a newly defined parameter called the normalized distribution volume (V Ã T ). In this method, a region containing receptors (the cerebellum) is selected and used as the input tissue region instead of a receptor-free reference tissue region. Mathematically, V Ã T is defined as V Ã T = V T /K 0 1 (V T normalized by the tracer delivery (K 0 1 ) of the input region). V Ã T is independent of regional blood flow (although it is linearly proportional to the tracer delivery or blood flow of the input region). Therefore, V Ã T may be a useful receptor parameter if an input region with tracer delivery (blood flow), which is unchanged between subject groups or experimental conditions can be defined. V Ã T and additionally relative tracer delivery (R 1 = K 1 /K 0 1 ) can then be estimated with the twoparameter multilinear reference tissue model (MRTM2; Ichise et al, 2003) . Two-parameter multilinear reference tissue model provides less noise in parametric images than does the original threeparameter MRTM.
Here, the new method was applied to human [ 18 F]FP-TZTP PET data described previously (Cohen et al, 2003) of healthy aged subjects with and without APOE-e4 alleles. As stated above, the gray matter of V T was shown previously to be higher in subjects with an APOE-e4 allele(s) (Cohen et al, 2003) . The hypothesis in this study was that V Ã T can also differentiate the two subject groups without the use of the arterial input function data. The use of MRTM2 requires estimation of k 0 2 (tracer clearance rate constant from the reference region or the input region-containing receptors in this study) by threeparameter MRTM (Ichise et al, 2003) . Therefore, conditions that might affect accurate estimation of k 0 2 were evaluated by computer data simulation analysis.
Theory
Estimation of the total distribution volume, V T , by 1T kinetic analysis (KA) applicable to 1T tracers such as [
18 F]FP-TZTP uses the following operational equation:
where C T (t) is the region of interest (ROI) or voxel tissue tracer concentration (kBq/cm 3 ), C P (t) the metabolite-corrected plasma tracer concentration (kBq/mL), and # the convolution symbol. Equation (1) allows nonlinear least-squares estimation of two parameters from the entire data set. V T is calculated as K 1 /k 2 .
Two-parameter multilinear reference tissue model (Ichise et al, 2003) , which is applicable to tracers such as [
18 F]FP-TZTP with 1T kinetics, is proposed to estimate the normalized distribution volume (V* = V/K 0 1 ) and relative tracer delivery (R 1 = K 1 /K 0 1 ) without the use of arterial input functions. Twoparameter multilinear reference tissue model can be expressed as
where C T (T) and C 0 T (T) are the ROI or voxel tissue tracer concentrations and the prime sign indicates the reference region (input region). Equation (2) involves two parameters (R 1 and k 2 ) if the value of k 0 2 is known a priori. Equation (2) is applicable to the entire time-activity data for [
18 F]FP-TZTP with 1T kinetics, that is for T > 0. Two-parameter multilinear reference tissue model (equation (2)) then allows estimation of R 1 and k 2 using an input region containing receptors, from which V
, if the input region has no receptors (then called the reference region). Therefore, the noise magnitude of V given a priori the correct value of k 2 0 , the noise magnitude of MRTM2 parameter estimation is nearly identical to that of 1TKA (Ichise et al, 2003) , because both are two-parameter methods. The value of k 0 2 can be estimated by the threeparameter MRTM using ROI time-activity curves (TACs) (Ichise et al, 2003) . The operational equation of MRTM is
Equation (3) estimates three parameters, R 1 , k 0 2 , and k 2 , using the input and target tissue TACs. We have shown previously that the bias and variability of k 0 2 estimation by MRTM increases with noise in the target ROI TAC (Ichise et al, 2003) . In addition, our preliminary analysis indicated that the magnitude of the bias and variability of k (3) (Wu and Carson, 2002) . The advantage of MRTM2 over SRTM2 is MRTM2's computational ease and therefore its greater suitability for parametric imaging (Ichise et al, 2003) .
Materials and methods

Positron Emission Tomography Data
The healthy human [
18 F]FP-TZTP PET data were selected from the study described previously (Cohen et al, 2003) . The subjects consisted of 19 aged healthy individuals (mean age = 6278 years; range: 52 to 75 years) in two groups, 10 (six men and four women) with one or more APOE-e4 alleles (APOE-e4( + )) and nine (four men and five women) without APOE-e4 alleles (APOE-e4(À)). The PET procedure has been described previously in detail (Cohen et al, 2003) . In brief, the PET study was approved by the NIMH Institutional Review Board and written informed consent was obtained from each subject. [
18 F] FP-TZTP PET scans were acquired in three-dimensional mode on the GE Advance tomograph (GE Medical Systems, Waukesha, WI, USA) for 120 mins (33 frames with scan duration ranging from 30 secs to 5 mins) after a bolus administration of 10.270.3 mCi of the tracer. The GE Advance acquires 35 simultaneous slices, with 4.25 mm interslice distance with a reconstructed spatial resolution of 6 to 7 mm in all directions. To reduce head motion, all subjects wore individualized thermoplastic facemasks that were fixed to the scanner headrest. Positron emission tomography scanning was preceded by an 8-min transmission scan to correct for attenuation.
Twenty-eight arterial blood samples were obtained, for the 120-min PET scanning. The parent fraction for the arterial input function was determined from extraction in ethyl acetate followed by thin-layer chromatography analysis. The product of the plasma activity and metabolite fraction curves generated a metabolite-corrected plasma curve. The resulting curve was used as the input function for estimation of 1T kinetic parameter values. Plasma protein binding was determined by measuring the plasma-free fraction (f P ) of parent compound using ultrafiltration.
To be used for image coregistration and anatomical reference, each subject had a 124-slice whole brain magnetic resonance imaging (MRI) scans on a General Electric SIGNA 1.5 T (GE Medical Systems) scanner using a T 1 -weighted three-dimensional gradient echo sequence with radio frequency spoiling (TR (repetition time)/TE (echo time)/flip angle, 24 ms/3 ms/451).
Positron Emission Tomography Study Analysis
The original reconstructed PET data were corrected for subject motion during the 120-min acquisition by registering each time frame to the subject's MR image using the automatic image registration (AIR) algorithm (Woods et al, 1993) in the image analysis software MEDx (Sensor Systems Inc., Sterling, VA, USA). Note that in the study described previously (Cohen et al, 2003) , parametric images of V T and K 1 were generated from PET data after MRI-based partial volume corrections. In this study, all parametric images were generated from the original motion-corrected PET data without partial volume corrections. For all nonlinear (equation (1)) and linear (equations (2 and 3)) fitting, scan data were weighted by (1/s.d.
2 ), where s.d. of the data was estimated based on the noiseequivalent counts as described previously (Carson et al, 1998) . All V T and V Ã T values were corrected for plasma-free fraction, f P .
Parametric images of V T and K 1 were generated from the motion-corrected data and metabolite-corrected arterial input functions by 1TKA (equation (1)) implemented in IDL (Research Systems Inc., Boulder, CO, USA). Parametric imaging of V Ã T and R 1 by MRTM2 (equation (2)) requires selection of an input region and preliminary estimation of k 0 2 by MRTM (equation (3)) from ROI data. First, the cerebellum was chosen as the input region, because cerebellar blood flow (K 0 1 ) is known to be unchanged with the current and related conditions considered in this study (Cohen et al, 2003) . Second, our preliminary data analysis (data not shown) and simulation analysis (see below) indicated that for accurate MRTM k To this end, ROI TACs from the cerebellum (B1,100 voxels, voxel size = 2.0 Â 2.0 Â 4.25 mm), thalamus (B600 voxels), and striatum (B200 voxels) were manually defined on the K 1 image fused with the coregistered MRI image using a fusion module in the pixel-wise kinetic modeling (PMOD) software (PMOD Group, Zurich, Switzerland). Multilinear reference tissue model (equation (3)) fitting was implemented in MATLAB (The MathWorks, Natick, MA, USA). The accuracy of MRTM k (2)) was performed in pixel-wise kinetic modeling installed on a personal computer workstation (Dell Computer Co., Austin, TX, USA, 1.7 GHz Pentium s IV/1 GB RAM running on Microsoft s Windows 2000, Microsoft Co., Redmond WA, USA). To compare the parameters, V T , K 1 , V Ã T , and R 1 , between the two groups of subjects with and without APOE-e4 alleles, several ROIs were defined on the K 1 image in addition to the striatum, thalamus, and cerebellum as above, which consisted of the frontal cortex (B1,100 voxels), cingulate gyrus (B200 voxels), temporal cortex (B600 voxels), parietal cortex (B600 voxels), occipital cortex (B800 voxels), and amygdala (B70 voxels). The region size weighted mean voxel parameter values of these six cerebral cortex regions were compared between the two subject groups by t-test.
Intersubject variability of parameters was defined as the coefficient of variation (CV = 100 Â s.d./group mean parameter value) and was averaged over the two subject groups. For all voxels defined by the ROIs, V Ã T and R 1 values were also calculated from the corresponding 1TKA parameter values and the 1TKA cerebellum (input region) parameter values. The accuracy of MRTM2 V Ã T and R 1 estimations was evaluated voxel-wise by calculating percent differences between MRTM2 and 1TKA. 1TKA V Ã T and R 1 values for the cerebral cortex were also compared between the two subject groups. Statistical significance was defined as P < 0.05.
Simulation Analysis
The computer simulation analysis was performed to evaluate the accuracy of k 0 2 estimation by MRTM. The steps taken for the simulation analyses are outlined in Table 1 .
Step 1. To calculate group mean parameter values that can be used for computer simulation analysis, ROI TACs were fitted by 1TKA using individual metabolite-corrected plasma input functions. The mean 1TKA parameter values from 11 subjects (Table 2) were then used to generate noise-free TAC data as described below in Step 3.
Step 2. ROI TAC percent noise was calculated based on deviations from 1TKA fitting (100 Â s.d./mean) for the latter portion of the TAC (60 to 120 mins) and the mean percent noise over these 11 subjects was calculated (Table 2) .
Step 3. Our preliminary simulation analysis suggested that the bias and variability of MRTM k 0 2 estimation at a typical ROI noise level are dependent on the k 2 /k 0 2 ratio and the magnitude of k 0 2 . Therefore, 1T TAC data were simulated in the k 2 /k 0 2 parameter space. To this end, one typical metabolite-corrected plasma input was selected from the subject group, and was scaled to a group mean injected dose of 10.2 mCi. Noise-free TACs for cerebellum (input region) and thalamus (target region) were simulated using the 1T parameter values derived from the group mean K 1 and k 2 values (n = 11) estimated by 1TKA for the respective regions (Table 2) for 120 mins (33 frames, the same sampling as used in actual PET data). Intravascular radioactivity was not included since its contribution would be minimal due to the high K 1 and V T values. The thalamus was chosen because k 2 /k 0 2 = 1.60 was highest. Then, another nine noise-free cerebellar TACs were Table 1 Simulation analysis steps
Step Procedure
1
Calculation of group mean 1TKA parameter values for the cerebellum and thalamus (Table 2)  2 Calculation of group mean thalamus TAC noise (1.5%, Table 2)  3 Generation of noise-free 1TKA TACs (cerebellum and thalamus) using the parameters derived from the group mean parameter values ( Table 2 ) (total of 10 cerebellum TACs and 10 Â 30 thalamus TACs in the k 2 /k 0 2 space) 4
For each thalamus TAC, 1,000 TACs were generated by adding random noise of 1.5% 5
Evaluation of the bias and variability of k 0 2 estimations using noise-free cerebellum TACs and noisy thalamus TACs in the k 2 /k
Generation of another set of 10 Â 30 thalamus TACs as in
Step 3 but TACS are perturbed with an addition of another tissue compartment (Appendix A) 7
Repeat
Step 4 to generate noisy thalamus TACs from those discrepant TACs generated in Step 6 8
Step 5 to evaluate the bias and variability of k 2 0 estimations using noise-free cerebellum TACs and noisy and discrepant thalamus TACs in the k 2 /k
1TKA, one-tissue kinetic analysis; TAC, time-activity curve. Step 4. Then, random amounts of normally distributed mean zero noise were added to the noise-free thalamus TACs using the noise model described previously (Ichise et al, 2003) . One thousand noisy TACs were generated for each of the thalamus TACs at a noise level of 1.5%, which was the mean % noise of 11 subjects (Table 2) (total of 1,000 Â 300 TACs).
Step 5. The accuracy of k 0 2 estimation was evaluated by calculating the bias (% deviation of the sample mean (n = 1,000) from the true value) and the variability (% sample s.d. relative to the true value). Weighted linear least-squares MRTM fitting was performed with weights equal to the inverse of the simulated data variance.
Step 6. Our preliminary simulation analysis suggested that substantial MRTM k 0 2 bias might be introduced by a slight discrepancy for the IT model. Therefore, for each of the 10 cerebellum TACs, another set of 30 thalamus TACs were generated in the same manner as above, except that another tissue compartment in parallel with the original 1T compartment was added as described in Appendix A.
Step 7.
Step 4 was repeated to generate noisy thalamus TACs from those discrepant TACs generated in Step 6.
Step 8.
Step 5 was repeated to evaluate the bias and variability of k 0 2 estimations using noise-free cerebellum TACs and noisy and discrepant thalamus TACs in the k 2 /k 0 2 space. All simulation analyses were performed in MATLAB and/or pixel-wise kinetic modeling.
Results
Positron Emission Tomography Study Analysis
Estimation of k 3 ) were 25, 21, 17, and 14%, respectively. Conversely, the mean R 1 values (0.9770.08, CV = 8%) estimated by MRTM2 were virtually identical to the mean R 1 values estimated by 1TKA (0.9770.08, CV = 8%), with mean percent voxelwise differences between the two methods (0.17 0.4%) and a very strong positive linear correlation between the two methods (r 2 E1.0, n = 19 subjects) ( Figure 1C) . Thus, despite the use of biased estimate of k 0 2 for MRTM2, R 1 estimation was unbiased and was very similar to R 1 estimation by 1TKA, whereas V Ã T showed a consistent bias.
APOE-e4( + ) versus APOE-e4(À). The mean MRTM2 V Ã T (mins) values (1,6597497) in APOE-e4( + )
were higher by 38% than those (1,2097233) in APOE-e4(À) ( Figure 3A) . Similarly, the 1TKA V T (mL/cm
3 ) values (701799) in APOE-e( + ) were higher by 22% than those (5777112) in APOEe4(À) ( Figure 3B ). However, the statistical significance for MRTM2 V Ã T comparison (P = 0.041) was slightly lower than that for 1TKA V T comparison (0.025) (Figure 3 ). There were no significant differences in the mean f P (P = 0.17) or K T and R 1 images were generated by the two-parameter multilinear analysis (MRTM2), whereas V T and K 1 images were generated by the nonlinear one-tissue kinetic analysis (1TKA). Images are normalized to the maximal voxel value within the brain displayed using a linear gray scale (white to black in descending voxel values). In contrast to the case with the data simulated by the perfect IT model, as described in detail in Appendix A, the bias of MRTM k 0 2 estimation for the slightly discrepant [
18 F]FP-TZTP 1T data was significantly biased ( Figure 5B) . However, the variability of k 0 2 estimation was essentially the same for the two data sets (Figures 4B and 5C ). The simulation data for the slightly discrepant 1T model also showed that both the bias and variability of MRTM k T was able to discriminate between APOEe4( + ) and APOE-e4(À) groups in a similar manner to that shown previously for V T . Thus, V Ã T may be a useful receptor parameter, which can be estimated noninvasively for tracers such as [
18 F]FP-TZTP without any suitable receptor-free reference region. Although this receptor parameter, V Ã T , was useful to make intergroup comparisons in this study, it should also be useful for within-subject comparisons in experimental paradigms to evaluate drug effects, activations, and so on), provided that K In this study, the receptor parameters, V Ã T and V T , were normalized by the plasma-free fraction, f P . Measurement of f P is actually no more invasive than is intravenous injection of the tracer. Measurements of f P requires only a small amount of venous blood obtained just before injection of the tracer from the same intravenous line for the tracer injection. Determination of f P is accomplished in vitro by ultrafiltration and no metabolite correction is needed. V T is the sum of V S (specific distribution volume) and V ND (nondisplaceable distribution volume). V S is proportional to the concentration of unoccupied or available receptor, B avail , as follows:
T by f P removes this nonreceptor factor, f P , from the parameters V T or V Ã T . The f P normalization is therefore appropriate when the plasma protein binding of radioligands has significant intersubject variability and/or it is different between subject groups. The intersubject variability of f P for [
18 F]FP-TZTP in this study was 20% and the mean subgroup f P was lower by 12% for the APOE-e4( + ) group than was for the APOE-e4(À), although this difference was not statistically significant. As was originally reported by Cohen et al, V T normalized by f P was significantly higher in the APOE-e4( + ) group than was in the APOE-e4( + ) group. Without this f P normalization, V T (mL/cm 3 ) was higher by 12% in the former (387 7) than in the latter (3575). However this V T difference was no longer statistically significant (P = 0.3). Likewise, V Ã T without f P normalization was higher by 18% in the former, but the difference was not statistically significant either.
In this study, V Ã T was normalized by f P to remove the contribution of plasma protein binding as explained above.
containing the K 1 /K 1 0 ratio. However, the normalization of V Ã T by f P does not cancel in this ratio for the following reason. The plasma-free fraction, f P , is the equilibrium-free fraction in plasma. In general, higher free fraction correlates (ideally linearly) with higher tracer activity levels in tissue and higher V T values. However, K 1 or K 1 0 is different; it is not an equilibrium value. In most cases, tracer easily comes off the protein and can enter the brain during one capillary transit, that is, f P does not linearly affect K 1 . If it did, then the highest possible value for K 1 would be f P Â CBF (cerebral blood flow). For [
18 F]TZTP, K 1 is equal to approximately 80% of CBF (as measured with [
15 O]water), as opposed to 10% of CBF (f P B10%). Thus, while there may be a mild correlation between K 1 or K 1 0 and f P , division of K 1 0 by f P is inappropriate. Therefore, V Ã T is affected linearly by f P , whereas the effects of f P on K 1 or K 1 0 are minor, that is, the predominant effect is in k 2 . Therefore, normalization by f P is appropriate for both V T and V (17%) . Therefore, the use of V Ã T would require a larger sample size to achieve the same significance as V T (see below). The relatively small intersubject variability of V T of only 17% and the fact that 1TKA showed excellent data fitting (data not shown) suggest that errors in the measurements of plasma radioligand activity including metabolite corrections were probably small in this study. The significant increase in the variability of MRTM2 V Ã T as compared with ITKA V T was caused by two factors in this study. First, although there were no differences in the mean input region K In this study, V T and K 0 1 were correlated positively (r = 0.17) in the APOE-e4(À) group and negatively (r = À0.43) in the APOE-e4( + ) group. Although neither of these correlations was statistically significant (i.e., random observation), these correlations affected the intersubject V Ã T variability of the two groups differently, such that the V Ã T variability (19%) in the APOE-e4(À) was similar to that of V T (19%), whereas it was considerably higher (30%) than that of V T (14%) in the APOE-e4( + ) group (Figure 3 ) (with the two groups combined, the variability of V Ã T was 25% and that of V T was 17%). Second, MRTM k 0 2 (25%) had a higher intersubject variability than that by 1TKA k 0 2 (22%), which also contributed to the higher variability of V Ã T . In the latter situation, our simulation study suggests that variability of MRTM k 0 2 can be significantly reduced if an input tissue region can be selected such that k 2 /k 0 2 is well away from unity. However, the availability of such an input region depends on the tracer.
The increase in intersubject variability of V Ã T (25%) as compared with V T (17%) with [ 18 F]FP-TZTP in this study reduced the statistical significance to P = 0.040 from P = 0.025. For V Ã T to have the same statistical significance as V T , the sample size would need to be increased. We performed a power analysis to calculate the required sample size (N) for a future study to detect the same mean differences as found in this study of V T or V Ã T between the two populations (APOE-e4( + ) and APOE-e4(À)) at a power of 80% and an a = 0.05 given the two subgroup pooled standard deviations of 124 mL/ cm À3 for V T and 489 min À1 for V Previously, we applied the MRTM2 to estimate BP ND with serotonin transporter imaging tracer, [ 11 C]DASB (Ichise et al, 2003) , where the cerebellum was chosen as an input region (receptor-free). The mean k 0 2 was very high (0.056 min À1 ) and k 2 /k 0 2 ranged from 0.23 to 0.38 (or k 0 2 /k 2 ranged from 2.6 to 4.3). The variability of MRTM k 0 2 estimation was small ( < 6%), which is consistent with our current simulation analysis results ( Figures 4B and 5C Figure 5 ). In our previous study with [
11 C]DASB, MRTM2 BP ND estimation was somewhat unstable in the white matter, which required R 1 -based thresholding of BP ND in the white matter to generate cosmetically appealing parametric images (Ichise et al, 2003) . However, for [
18 F]FP-TZTP, MRTM2 V Ã T parameter estimation was stable everywhere including the white matter. We have shown previously that MRTM2 parameter estimates are nearly identical to those of 1TKA when a correct value of k 0 2 is used (Ichise et al, 2003) . Here, we used substantially biased values of k (1)). As was the case with [ 11 C]DASB, this study confirms that R 1 estimation is more stable than BP ND or V Ã T . In addition, the parameter estimates from MRTM2 and the nonlinear version of MRTM2, that is, SRTM2 (Wu and Carson, 2002) , were nearly identical with the [
18 F]FP-TZTP PET data (data not shown). The major advantage of the MRTM2 (or SRTM2) over its three-parameter version (MRTM or SRTM) is that there is no noise increases in parametric images for the former compared with 1TKA, as opposed to substantial noise increases in parametric images for the latter (Ichise et al, 2003; Wu and Carson, 2002) .
Although R 1 may not be a primary parameter of interest, the R 1 parametric image can be very useful, for example, for MRI-PET coregistration. In this study, to define ROIs for the MRTM k 0 2 estimation, we used K 1 and MRI images, because K 1 images were available in this study. However, the fact that MRTM2 allows generation of accurate, low-noise R 1 parametric images even when MRTM k 0 2 is biased suggests that we could perform MRTM2 parametric imaging in two steps. In the first step, ROIs (cerebellum and thalamus) are drawn on the summed PET raw images. These ROIs are then applied to dynamic PET data. Then a preliminary k 0 2 value is obtained by MRTM fitting of these ROI TACs. This initial k 0 2 allows generation of preliminary R 1 images by MRTM2. In the second step, these preliminary R 1 images in conjunction with MRI can be used to define more accurate ROIs (cerebellum, thalamus, and striatum). Then, the MRTM k 0 2 estimation and MRTM2 procedures are repeated to generate final V Ã T and R 1 images. Although this strategy requires two steps, computation time for MRTM2 parametric imaging is quite small.
Finally, this V Ã T method was applied to a 1T tracer, [ 18 F]FP-TZTP, in this study. MRTM2, however, is also applicable to 2T tracers that have appropriate receptor-free reference tissue to estimate BP ND , by analyzing TAC data from a time point (t*) beyond which the operational equation (equation (3)) becomes linear. From equation (3), it is theoretically feasible to define V Ã T for tracers with 2T kinetics so long as the input region has 1T kinetics. However, the accuracy and precision of this method for 2T tracers need to be evaluated in the future.
Conclusions
The normalized distribution volume, V Ã T , defined as distribution volume V T normalized by the tracer delivery of an input region (K 0 1 ) containing receptors, can be estimated by MRTM2 without a receptor-free reference region and arterial blood. V Ã T can be used to identify group differences in receptor binding. However, V Ã T may require a larger sample size to identify the group differences in receptor binding with the same statistical significance as V T . This noninvasive MRTM2 V Ã T estimation method, which also allows estimation of relative tracer delivery (R 1 ) can be a useful data analysis tool for receptor-binding tracers such as [ 18 F]FP-TZTP with no receptor-free reference region.
